Icecure Medical is trading at $1.11, up 5.71% on October 21, 2026, likely supported by the enrollment of the first two patients at U.S. sites in its ProSense breast cancer cryoablation study. - The company announced the enrollment on October 20. - The study plans to enroll about 400 patients across up to 30 U.S. sites. Healthcare sector strength may also provide a supportive backdrop, but enrollment is the clearest specific catalyst.